The Election Committee of Active Biotech AB proposes Michael Shalmi to be appointed new Chairman of the Board and Uli Hacksell to be appointed new member of the Board - Seite 2
Uli Hacksell, born in 1950, is a pharmacist, Doctor of Pharmaceutical Science and associate Professor at Uppsala University. He is acting CEO and member of the Board of Medivir AB. In addition, Uli Hacksell holds a position as Chairman of the Board of Adhera Therapeutics Inc. and as member of the Board of Beactica AB, Cerecor Inc, InDex Pharmaceuticals AB and Uppsala University.
For further information on the proposed members of the Board of Directors, please see the Election Committee's complete proposal which is available at Active Biotech's website, www.activebiotech.com.
Other information
The Election Committee has been informed that Active Biotech intends to enter into a consulting agreement with Michael Shalmi, pursuant to which Michael Shalmi and the management of the company
jointly shall develop a new business plan for the company based on a full evaluation of the clinical and commercial opportunities of Active Biotech's assets. This task, which is an assignment
outside the scope of Michael Shalmi's task as Chairman of the Board, shall be carried out during the period up to and including December 31, 2019, for which it is intended that Michael Shalmi shall
receive a remuneration of SEK 1.1 million for the assignment.
In addition, the Election Committee has been informed that the main owners of Active Biotech, MGA Holding and Nordstjernan, have issued call options on market terms for 1.500.000 shares in Active Biotech to Michael Shalmi.
For further information, please contact:
Helén Tuvesson, CEO
Tel. +46 46 19 21 56
Hans Kolam, CFO
Tel. +46 46 19 20 44
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties in development for neurodegenerative diseases. ANYARA (naptumumab), an immunotherapy, in development for cancer indications in partnership with NeoTX Therapeutics Ltd. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod and SILC projects. Please visit www.activebiotech.com for more information.
Lesen Sie auch
Active Biotech AB
(org.nr 556223-9227)
Box 724, 220 07 Lund
Tel. +46 46 19 20 00
This information is information that Active Biotech AB is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the contact person set out above, at 13.00 p.m. CET on May 2, 2019.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire